(Sharecast News) - Hutchmed China said on Friday that new and updated clinical data from several of its drug candidates would be presented at two major oncology meetings this month, including the World Conference on Lung Cancer (WCLC) in Barcelona and the Chinese Society of Clinical Oncology (CSCO) annual meeting in Jinan.

• Read full story

• News Channel

(Sharecast News) - Hutchmed China said in an update on Wednesday that it has completed patient enrollment in its phase three 'Sanovo' trial in China testing a combination of 'Orpathys', or savolitinib, and 'Tagrisso', or osimertinib, as a first-line therapy for certain non-small cell lung cancer patients.

• Read full story

• News Channel

(Sharecast News) - Hutchmed announced on Monday that China's National Medical Products Administration (NMPA) has approved the new drug application for the combination of 'Orpathys'. Or savolitinib, and 'Tagrisso', or osimertinib, to treat patients with locally advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer (NSCLC) with MET amplification following progression on EGFR TKI therapy.

• Read full story

• News Channel